iPSC– tag –
-
BioInformant Report Outlines 2026 iPSC-Derived Cell Therapeutic Pipeline, Highlighting Safety Challenges and Key Developers
BioInformant USA Overview This article provides an overview of a market research report by BioInformant, focusing on the 2026 pipeline for iPSC-derived cell therapeutics. The report analyzes the current state and future challenges, ident... -
iPSC Product Quality Defined in Differentiation: Core of Process Development for GMP Manufacturing
Made Scientific USA Overview Made Scientific highlights that the quality of iPSC-derived products is established during the differentiation development phase, making subsequent improvements challenging. Current differentiation protocols ... -
2026 iPSC Industry Report: Allogeneic Therapies Surpass Autologous, Diabetes, Parkinson’s, AMD Clinical Trials Progress
BioInformant Global Overview The 2026 iPSC Industry Report by BioInformant details advancements in iPSC technology for therapeutic applications, disease modeling, drug discovery, personalized medicine, and toxicity testing. Notably, allo... -
Sana Biotechnology Targets 2026 IND for iPSC-Derived Hypoimmune Pancreatic Islet Cell Therapy SC451 in Type 1 Diabetes
TipRanks / Sana Biotechnology, Inc. USA Overview Sana Biotechnology updated its investor presentation, emphasizing pipeline advancements, particularly for SC451, an iPSC-derived hypoimmune pancreatic islet cell therapy for Type 1 diabete... -
Fate Therapeutics to Detail iPSC-Derived Cellular Immunotherapy Pipeline at Cantor Global Healthcare Conference
Fate Therapeutics Press Releases / Barchart.com USA Overview Fate Therapeutics announced its management will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, September 9-12, 2026. The company plans t... -
Fate Therapeutics to Present Encore Clinical Data for iPSC-Derived FT819 in Systemic Scleroderma
Fate Therapeutics, Inc. Investors USA Overview Fate Therapeutics will re-present clinical data for FT819, its iPSC-derived, off-the-shelf CAR T-cell product candidate, at the CCR – West 2026 conference. The data potentially shows early c... -
Nanjing Drum Tower Hospital Engineers Stem Cell Patch for Cardiac Regeneration: A New Frontier in Heart Failure Treatment
Nanjing Drum Tower Hospital China Overview Nanjing Drum Tower Hospital, in collaboration with a Korean lab, has achieved a significant breakthrough in stem cell-based heart regeneration. Their novel bioengineered cardiac patch, leveragin... -
Parkinson’s Regenerative Medicine Milestone: iPSC-Derived Dopamine Precursors Safely Transplanted in First-in-Human Trial
Parkinson's NSW Sweden Overview A pivotal clinical trial led by Lund University has confirmed the safety and feasibility of transplanting iPSC-derived dopamine precursor cells into Parkinson's disease patients. Published in Nature Medici... -
Autologous iPSCs from PAD Patients Demonstrate Therapeutic Equivalence to Healthy Donors, Propelling Personalized Vascular Regeneration
CELL STEM CELL International Overview A recent study has demonstrated that induced pluripotent stem cells (iPSCs) and their endothelial cell derivatives (iPSC-ECs) generated from peripheral artery disease (PAD) patients exhibit character... -
Next-Gen Brain Organoids Reveal How APOE4 Astrocytes Drive Alpha-Synuclein Pathology, Unlocking New Therapeutic Targets
ALZFORUM USA Overview A novel mechanism by which APOE4, a major Alzheimer's risk gene, exacerbates neuropathology has been published in Cell Stem Cell, leveraging a newly developed human brain organoid model termed 'miBrains.' This six-c...
